<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN" "http://jats.nlm.nih.gov/publishing/1.2/JATS-journalpublishing1.dtd">
<article article-type="research-article" dtd-version="1.2" xml:lang="ru" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="issn">2658-6533</journal-id><journal-title-group><journal-title>Научные результаты биомедицинских исследований</journal-title></journal-title-group><issn pub-type="epub">2658-6533</issn></journal-meta><article-meta><article-id pub-id-type="doi">10.18413/2313-8955-2018-4-4-0-1</article-id><article-id pub-id-type="publisher-id">1537</article-id><article-categories><subj-group subj-group-type="heading"><subject>Генетика</subject></subj-group></article-categories><title-group><article-title>Ассоциация полиморфизма T1565C гена ITGB3 с развитием атеросклероза и ин-стент рестеноза коронарных артерий у пациентов со стабильной ишемической болезнью сердца</article-title><trans-title-group xml:lang="en"><trans-title>Association of the ITGB3 gene T1565C polymorphism with the development of atherosclerosis and in-stent restenosis in patients with stable coronary artery disease</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="ru"><surname>Богатырева</surname><given-names>Калима Бадиноковна</given-names></name><name xml:lang="en"><surname>Bogatyreva</surname><given-names>Kalima B.</given-names></name></name-alternatives><email>Kalima.bogatyreva@mail.ru</email></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="ru"><surname>Азова</surname><given-names>Мадина Мухамедовна</given-names></name><name xml:lang="en"><surname>Azova</surname><given-names>Madina M.</given-names></name></name-alternatives></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="ru"><surname>Агаджанян</surname><given-names>Анна Владимировна</given-names></name><name xml:lang="en"><surname>Aghajanyan</surname><given-names>Anna V.</given-names></name></name-alternatives></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="ru"><surname>Цховребова</surname><given-names>Лейла Вахтанговна</given-names></name><name xml:lang="en"><surname>Tskhovrebova</surname><given-names>Leila V.</given-names></name></name-alternatives></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="ru"><surname>Аит</surname><given-names>Аисса Амира</given-names></name><name xml:lang="en"><surname>Ait</surname><given-names>Aissa A.</given-names></name></name-alternatives></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="ru"><surname>Шугушев</surname><given-names>Заурбек Хасанович</given-names></name><name xml:lang="en"><surname>Shugushev</surname><given-names>Zaurbek Kh.</given-names></name></name-alternatives></contrib></contrib-group><pub-date pub-type="epub"><year>2018</year></pub-date><volume>4</volume><issue>4</issue><fpage>0</fpage><lpage>0</lpage><self-uri content-type="pdf" xlink:href="/media/medicine/2018/4/ilovepdf_com-4-10.pdf" /><abstract xml:lang="ru"><p>Актуальность: На сегодняшний день чрескожные коронарные вмешательства являются одним из самых эффективных методов лечения ишемической болезни сердца (ИБС). Несмотря на непрерывное совершенствование методик и дизайнов стентов, рестеноз внутри стента (РВС) остается одним из главных ограничивающих факторов данной процедуры.&amp;nbsp; Исследования в области молекулярной кардиологии показали значительный вклад дисфункции эндотелия в развитие РВС.&amp;nbsp; Согласно литературным данным, интегрин бета 3 вовлечен в межклеточные взаимодействия, взаимодействие с внеклеточным матриксом, влияет на активность гладкомышечных клеток, что в конечном итоге, может приводить к гиперплазии неоинтимы. Цель исследования: Изучить возможность ассоциации полиморфизма T1565C гена ITGB3 с развитием рестеноза после стентирования коронарных артерий. Материалы и методы: В исследование были включены пациенты, страдающие ИБС, которым ранее проводилось интракоронарное стентирование стентами с лекарственным покрытием (n=110), и пациенты с интактными сосудами по данным ангиографии (n=62). Повторное сужение сосуда в месте имплантации стента более 50% определялось как ангиографический рестеноз. Критерии включения в исследование: возраст &amp;gt; 45 лет, русские, атеросклероз по данным ангиографии одного или нескольких сосудистых бассейнов, согласие пациентов на исследование. Для генотипирования по полиморфизму T1565C гена ITGB3 применялась методика ПЦР в режиме реального времени. Результаты: Частоты аллеля С и гетерозиготного генотипа ТС достоверно выше в подгруппах пациентов с более ранним развитием рестеноза и диффузным поражением коронарного русла с наличием окклюзий.&amp;nbsp; Заключение: Минорный аллель С по полиморфизму T1565C гена ITGB3 можно рассматривать в качестве предиктора диффузного поражения коронарных артерий с развитием окклюзий и РВС коронарных артерий до одного года после процедуры стентирования.</p></abstract><trans-abstract xml:lang="en"><p>Background: Today, percutaneous coronary intervention (PCI) is the most effective treatment of coronary artery disease (CAD). Despite all technical advances in stent designs and techniques, in-stent restenosis (ISR) remains one of the main limiting factors of this procedure. Studies in the field of molecular cardiology have shown a significant contribution of endothelial dysfunction in the development of ISR. According to the literature, integrin beta 3 is involved in intercellular interactions, interaction with extracellular matrix; it influences the activity of smooth muscle cells, which can lead to neointimal hyperplasia. The aim of the study: To study the possibility of association of T1565C polymorphism of the ITGB3 gene with the development of restenosis after stenting of the coronary arteries. Materials and methods: Patients with CAD after PCI with drug-coated stents (n = 110) and patients with intact vessels according to angiography (n = 62) were included in the study. The repeated stenosis of the artery at the stent implantation site of more than 50% was defined as angiographic restenosis. The criteria for inclusion in the study were: age &amp;gt; 45 years, ethnic Russians, atherosclerosis according to the angiography of one or more arteries, patient informed consent. The genotyping for the ITGB3 T1565C polymorphism was performed using the real-time PCR. Results: The C allele and heterozygous genotype frequencies are significantly higher in groups of patients with earlier development of restenosis and diffuse CAD with occlusion. Conclusion: The minor C allele of the ITGB3 T1565C polymorphism may be considered as a predictor of diffuse CAD with the development of occlusions and ISR of the coronary arteries within the first year after stent implantation.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>атеросклероз</kwd><kwd>рестеноз</kwd><kwd>генные полиморфизмы</kwd><kwd>интегрин бета 3</kwd></kwd-group><kwd-group xml:lang="en"><kwd>atherosclerosis</kwd><kwd>restenosis</kwd><kwd>gene polymorphisms</kwd><kwd>integrin beta 3</kwd></kwd-group></article-meta></front><back><ref-list><title>Список литературы</title><ref id="B1"><mixed-citation>European cardiovascular disease statistics / M. Nichols [et al.]. 2012. N. 2012. DOI:978-2-9537898-1-2.</mixed-citation></ref><ref id="B2"><mixed-citation>Global Burden ofDisease Study 2013 (GBD 2013). Age-Sex Specific All-Cause and Cause-Specific Mortality 1990-2013. Seattle, United States: Institute for Health Metrics and Evaluation (IHME), 2014.</mixed-citation></ref><ref id="B3"><mixed-citation>2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions / G.N. Levine [et al.] // J Am Coll Cardiol. 2011. Vol. 58(24). P. e44-122. DOI: 10.1016/j.jacc.2011.08.007</mixed-citation></ref><ref id="B4"><mixed-citation>Marco J. Drug Eluting Stents: promises and the precautionary attitude (Gr&amp;uuml;entzig lecture at the ESC Stockholm, 2005) // EuroIntervention. 2006. Vol. 2(1). P. 15-17.</mixed-citation></ref><ref id="B5"><mixed-citation>Statistics &amp;ndash; 2011 Update A Report From the American Heart Association / V.L. Roger [et al.] // Circulation. 2011. Vol. 123(4). P. e18-e209. DOI:10.1161/CIR.0b013e3182009701</mixed-citation></ref><ref id="B6"><mixed-citation>Restenosis after PCI. Part 1: pathophysiology and risk factors / J.W. Jukema [et al.] // Nat Rev Cardiol. 2012. N 9. P. 53-62.</mixed-citation></ref><ref id="B7"><mixed-citation>Indolfi C., Pavia M., Angelillo I.F. Drug-eluting stents versus bare metal stents in percutaneous coronary interventions (a meta-analysis) // Am J Cardiol. 2005. Vol. 95(10). P. 1146-1152. DOI: https://doi.org/10.1016/j.amjcard.2005.01.040</mixed-citation></ref><ref id="B8"><mixed-citation>Coronary artery stretch versus deep injury in the development of in-stent neointima / J. Gunn [et al.] // Heart. 2002. N 88. P. 401-405. DOI: http://dx.doi.org/10.1136/heart.88.4.401</mixed-citation></ref><ref id="B9"><mixed-citation>Morphological predictors of restenosis after coronary stenting in humans / R. Virmani [et al.] // Circulation. 2002. N 105. P. 2974-2980. DOI: 10.1161/01.CIR.0000019071.72887.BD</mixed-citation></ref><ref id="B10"><mixed-citation>Association of coronary microvascular dysfunction with restenosis of left anterior descending coronary artery disease treated by percutaneous intervention / A. De Vita [et al.] // Int J Cardiol. 2016. N 219. P. 322-325. DOI: https://doi.org/10.1016/j.ijcard.2016.06.031</mixed-citation></ref><ref id="B11"><mixed-citation>Boyle C.J., Lennon A.B., Prendergast P.J. In silico prediction of the mechanobiological response of arterial tissue: application to angioplasty and Stenting // J. Biomech. Eng. 2011. Vol. 133(8) 81001. DOI:10.1115/1.4004492.</mixed-citation></ref><ref id="B12"><mixed-citation>Computational simulation methodologies for mechanobiological modelling: a cell-centred approach to neointima development in stents / C.J. Boyle [et al.] // Philos Trans A Math Phys Eng Sci. 2010. Vol. 368(1921). P. 2919-2935. DOI: 10.1098/rsta.2010.0071</mixed-citation></ref><ref id="B13"><mixed-citation>Munk P.S., ButtN., Larsen A. Endothelial dysfunction predicts clinical restenosis after percutaneous coronary intervention // Scand Cardiovasc J. 2011. Vol. 45(3). P. 139-45. DOI: https://doi.org/10.3109/14017431.2011.564646</mixed-citation></ref><ref id="B14"><mixed-citation>Association of polymorphisms in platelet and hemostasis system genes with acute myocardial infarction / J.W. Knowles [et al.] // Am Heart J. 2007. Vol. 154(6). P. 1052-8. DOI: https://doi.org/10.1016/j.ahj.2007.05.021</mixed-citation></ref><ref id="B15"><mixed-citation>Platelet glycoprotein Ib&amp;alpha; and integrin &amp;alpha;2&amp;beta;1 polymorphisms: gene frequencies and linkage disequilibrium in a population diversity panel / J. Di Paola [et al.] // J Thromb Haemost. 2005. N 3. P. 1511-21. DOI: https://doi.org/10.1111/j.1538-7836.2005.01273.x</mixed-citation></ref><ref id="B16"><mixed-citation>Somanath P.R., Malinin N.L.,&amp;nbsp;Byzova T.V. Cooperation between integrin alphavbeta3 and VEGFR2 in angiogenesis // Angiogenesis. 2009. Vol. 12(2). Р. 177-185. DOI: 10.1007/s10456-009-9141-9</mixed-citation></ref><ref id="B17"><mixed-citation>Platelet glycoprotein IIIa Leu33Pro gene polymorphism and coronary artery disease: A meta-analysis of cohort studies / M. Verdoia [et al.] // Platelets. 2015. Vol. 26(6). P. 530-535. DOI: https://doi.org/10.3109/09537104.2014.948839</mixed-citation></ref><ref id="B18"><mixed-citation>Yee D.L., Bray P.F. Clinical and functional consequences of platelet membrane glycoprotein polymorphisms // Semin Thromb Hemost. 2004. Vol. 30(5). P. 591-600. DOI: 10.1055/s-в 2004-835679</mixed-citation></ref><ref id="B19"><mixed-citation>Integrin beta3 regulates clonality and fate of smooth muscle-derived atherosclerotic plaque cells / A. Misra [et al.] // Nat Commun. 2018. Vol. 9(1). P. 2073. DOI: https://doi.org/10.1038/s41467-018-04447-7</mixed-citation></ref><ref id="B20"><mixed-citation>Shoenfeld Y., Harats D., Wick G. Atherosclerosis and Autoimmunity 1st Edition.2001. V. 2.P. 349.</mixed-citation></ref></ref-list></back></article>